Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA / Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients
Rev. méd. Chile
; 135(5): 573-579, mayo 2007. ilus, tab, graf
Article
em Es
| LILACS
| ID: lil-456673
Biblioteca responsável:
BR1.1
ABSTRACT
Background:
Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective.Aim:
To report the experience in our Health Centre with rapamycin-eluting stents. Patients andmethods:
Forty two stents with rapamicine were implanted to 32 diabetic patients, between June 2002 and December 2004. After the procedure, subjects were clinically followed-up for an average period of 19.9+9.9 months, evaluating functional capacity, angina pectoris, dyspnea, need for hospital admission, acute coronary events and cardiac death. In those subjects clinically suspected to have restenosis, a coronary angiography was performed.Results:
Twenty-nine subjects (90.6 percent) remained asymptomatic, two subjects (6.3 percent) developed angina pectoris but restenosis was ruled out, and one subject (3.1 percent) died.Conclusions:
The use of rapamycin-eluting stents in these patients was safe and successful with no evidence of clinic restenosis. These positive results are similar to those reported in the Diabetes Study.
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Angioplastia
/
Sirolimo
/
Estenose Coronária
/
Angiopatias Diabéticas
/
Stents Farmacológicos
/
Imunossupressores
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
Idioma:
Es
Ano de publicação:
2007
Tipo de documento:
Article